A Randomized, Double-Blind, Placebo-Controlled; Phase 1b, Safety, Tolerability, and Pharmacokinetic Study of Multiple Ascending Doses of GC021109 in Subjects With Mild to Moderate Alzheimer's Disease
Phase of Trial: Phase I
Latest Information Update: 12 Feb 2016
At a glance
- Drugs GC 021109 (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions
- Sponsors GliaCure
- 07 Jun 2017 Biomarkers information updated
- 14 Dec 2015 According to a GliaCure media release, the company reported pooled clinical results from this and other trial (249753 ) for the treatment of Alzheimer's disease.
- 14 Dec 2015 According to a GliaCure media release, Status changed from recruiting to completed.